""

Carcinoma of Unknown Primary (CUP)

Recruiting after consultation
Open recruiting

Neoadjuvant Therapy

There are currently no studies available

Adjuvant Therapy

There are currently no studies available

Metastatic Disease: First-Line-Therapy

Title: A Phase II, Randomized, Active controlled, Multi-Center study comparing efficacy and safety of targeted therapy or cander immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patinets with CUP who have received three cycles of platinum doublet chemotherapy
Phase: II
Contact: Marie-Christin Vollmer / Study Nurse
Clinical Investigator: Prof. Dr. Alwin Krämer
Registration: Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe NCT03498521
EudraCT-Number: (siehe EU klinisches Studienregister) 2017-003040-20

Metastatic Disease: Follow-Up Care

Title: A phase II, open-label, non-randomized, multi-center study evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or refractory to platinum-based chemotherapy (CheCUP)
Phase: II
Contact: Marie-Christin Vollmer / Study Nurse
Clinical Investigator: Prof. Dr. Alwin Krämer
Registration: Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe NCT04131621
EudraCT-Number: (siehe EU klinisches Studienregister) 2018-004562-33

Surgical Study

There are currently no studies available

Radiotherapy Study

There are currently no studies available

Other study

There are currently no studies available